Skip to main content

Table 1 Clinical characteristics

From: The number of methylated CpG sites within the MGMT promoter region linearly correlates with outcome in glioblastoma receiving alkylating agents

Gender
 Male/female, (n/n, %/%) 142 (66.0)/73 (34.0)
Age (years)
 Median (range) 60 (17–86)
KPS  
 Median (range) 80 (40–100)
Tumor side
 Left/right (n/n, %/%) 117 (54.4)/98 (46.6)
Tumor location
 Lobar/deepa/multifocal (n/n/n, %/%/%) 139 (64.7)/20 (9.3)/56 (26.0)
Surgical treatment
 GTR (n, %) 63 (29.3%)
 STR (n, %) 37 (17.2%)
 Biopsy (n, %) 115 (53.5%)
  1. aDeep seated = not lobarly located (e.g. thalamus or basal ganglia)